Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Liraglutide

Liraglutide

GLP-1 · s.c. daily · Novo Nordisk / generics

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 2 trials with results · 52 registered trials · see on the pipeline board

Summary

Also known as
Saxenda / generics
Mechanism
GLP-1
Route
s.c. daily
Company
Novo Nordisk / generics
Highest development stage
approved
Status (as of data cut)
Approved for obesity (2014); generics available verify
Next milestone
—

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity4 approved / in labelFDA and EMA: SaxendaSaxenda EPAR
T2D4 approved / in labelFDA and EMA: VictozaVictoza EPAR
CV outcomes4 approved / in labelFDA label (Victoza): MACE reduction in T2D with established CVDLEADER
CKD1 phase 2 / signalKidney outcomes only as a LEADER secondary endpoint; no dedicated phase 3LEADER
HFpEF1 phase 2 / signalPhase 2 only
MASH1 phase 2 / signalPhase 2 only (LEAN)
Sleep apnoea3 positive phase 3Positive phase 3 (SCALE Sleep Apnea, results posted); not a labelled indicationSCALE Sleep Apnea
Knee OA-1 negative phase 3/4LOSEIT (phase 4): no reduction in knee pain versus placebo after diet-induced weight lossLOSEIT
Alzheimer's1 phase 2 / signalPhase 2b (ELAD) only

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

US prescribing information: indications

Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.

Liraglutide US label 27.07.2026

1 INDICATIONS AND USAGE Liraglutide Injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use : Liraglutide Injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Limitations of Use : Coadministration with other liraglutide-containing products is not recommended.

DailyMed

Victoza US label 14.10.2025

1 INDICATIONS AND USAGE VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use: VICTOZA contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. VICTOZA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. (1) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) Limitations of Use : • Coadministration with other liraglutide-containing products is not recommended.

DailyMed

Xultophy 100/3.6 US label 14.10.2025

1 INDICATIONS AND USAGE XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [see Warnings and Precautions ( 5.5 )]. • XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis. • XULTOPHY 100/3.6 has not been studied in combination with prandial insulin. XULTOPHY 100/3.6 is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : ( 1 ) • Coadministration with any other product containing liraglutide or another GLP-1 receptor agonist is not recommended. • Not recommended for the treatment of diabetic ketoacidosis. • Has not been studied in combination with prandial insulin.

DailyMed

liraglutide US label 18.06.2026

1 INDICATIONS AND USAGE Liraglutide injection is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. The safety and effectiveness of liraglutide injection in pediatric patients with type 2 diabetes have not been established. Liraglutide injection is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and Pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: Coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. ( 1 ) The safety and effectiveness of liraglutide injection in pediatric patients with type 2 diabetes have not been established. ( 1 )

DailyMed

Saxenda US label 25.02.2026

1 INDICATIONS AND USAGE SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. • Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. • The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use: • Coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. ( 1 ) • The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ( 1 )

DailyMed

LIRAGLUTIDE US label 12.03.2026

1 INDICATIONS AND USAGE Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use : Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) Limitations of Use: Coadministration with other liraglutide-containing products is not recommended.

DailyMed

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Outcome trials

Cardiovascular and kidney outcome trials

LEADER liraglutide 1.8 mg vs placebo · T2D at high CV risk · n = 9340 · 2016 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death, nonfatal (including silent) MI, or nonfatal stroke
0.870.78–0.97608 vs 694verified
Cardiovascular death
Death from cardiovascular causes
0.780.66–0.93219 vs 278verified
All-cause death
Death from any cause
0.850.74–0.97381 vs 447verified
Myocardial infarction
Myocardial infarction (fatal or nonfatal); not prespecified analysis
0.860.73–1.00292 vs 339verified
Stroke
Stroke (fatal or nonfatal); not prespecified analysis
0.860.71–1.06173 vs 199verified
Hospitalisation for heart failure
Hospitalization for heart failure
0.870.73–1.05218 vs 248verified
Kidney composite
Nephropathy: new-onset persistent macroalbuminuria, doubling of serum creatinine with eGFR <=45, continuous renal-replacement therapy, or death from renal disea
0.780.67–0.92268 vs 337verified
Expanded MACE (MACE + HF hosp. + revasc. + UA)
Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or heart failure
0.880.81–0.96948 vs 1062verified
Retinopathy complications
Retinopathy: need for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage, or onset of diabetes-related blindness
1.150.87–1.52106 vs 92verified
Coronary revascularisation
Coronary revascularization
0.910.80–1.04405 vs 441verified
Hospitalisation for unstable angina
Hospitalization for unstable angina pectoris
0.980.76–1.26122 vs 124verified
Verbatim quotes (11)
  • 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 1
    The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% CI, 0.78 to 0.97
  • Cardiovascular death · Results, Cardiovascular Outcomes; Table 1
    Death from cardiovascular causes occurred in fewer patients in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93
  • All-cause death · Results, Cardiovascular Outcomes; Table 1
    The rate of death from any cause was also lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97
  • Myocardial infarction · Table 1
    Myocardial infarction § 292 (6.3) 1.6 339 (7.3) 1.9 0.86 (0.73–1.00) 0.046
  • Stroke · Table 1
    Stroke § 173 (3.7) 1.0 199 (4.3) 1.1 0.86 (0.71–1.06) 0.16
  • Hospitalisation for heart failure · Table 1
    Hospitalization for heart failure 218 (4.7) 1.2 248 (5.3) 1.4 0.87 (0.73–1.05) 0.14
  • Kidney composite · Table 1; Results, Microvascular Outcomes
    Nephropathy 268 (5.7) 1.5 337 (7.2) 1.9 0.78 (0.67–0.92) 0.003
  • Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 1
    Expanded composite outcome ‡ 948 (20.3) 5.3 1062 (22.7) 6.0 0.88 (0.81–0.96)
  • Retinopathy complications · Table 1, microvascular outcomes
    Retinopathy 106 (2.3) 0.6 92 (2.0) 0.5 1.15 (0.87–1.52)
  • Coronary revascularisation · Table 1
    Coronary revascularization 405 (8.7) 2.3 441 (9.4) 2.5 0.91 (0.80–1.04)
  • Hospitalisation for unstable angina · Table 1
    Hospitalization for unstable angina pectoris 122 (2.6) 0.7 124 (2.7) 0.7 0.98 (0.76–1.26)

Other indications

ELAD Liraglutide · Mild cognitive impairment + T2D · 48 weeks · n = 396 congress

MCI reversal 49.5 % vs 20.4 % on linagliptin (EASD 2026)

MeasureDrugControlDifference (95 % CI)Status
Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline
week 52
——−0.2 (−0.4 to +0.1) FDG-PET SUVverified
Verbatim quotes (1)
  • Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline
    The primary outcome showed no significant differences in cerebral glucose metabolism (difference = -0.17; 95% confidence interval: -0.39 to 0.06; P = 0.14) between the two groups.

Registered trials (52)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
INFLAM MOTION
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
Knee OAPhase 2completed2025-06 → 2026-08130Completed; results not in the atlas yetNCT07225829
MODY
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
OtherPhase 2recruiting2025-05 → 2026-0850recruitingNCT07029009
NCT06361238
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
NeurologyPhase 3recruiting2024-11 → 2027-03260recruitingNCT06361238
NCT05965908
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
ObesityPhase 3completed2024-08 → 2025-11183Completed; results not in the atlas yetNCT05965908
NCT06559722 · China
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
T2DPhase 3unknown2024-08 → 2025-10510unknownNCT06559722
NCT05952882
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
ObesityPhase 3unknown2023-11 → 2025-12188unknownNCT05952882
NCT05767255
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
T2DPhase 3unknown2022-12 → 2023-0866unknownNCT05767255
NCT04763564
Efficacy of Liraglutide Therapy in Patients With IPAA
OtherPhase 2terminated2022-03 → 2023-108TerminatedNCT04763564
NCT04199728
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
AddictionPhase 2completed2021-10 → 2023-0927Completed; results not in the atlas yetNCT04199728
SCALE KIDS
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
ObesityPhase 3active not recruiting2021-03 → 2023-0878active not recruitingNCT04775082
NCT05360147
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
Alzheimer'sPhase 3completed2021-01 → 2021-0430Completed; results not in the atlas yetNCT05360147
NCT04605861
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
ObesityPhase 3completed2020-08 → 2022-12414Completed; results not in the atlas yetNCT04605861
NCT04487743
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities
ObesityPhase 3unknown2020-05 → 2022-06300unknownNCT04487743
NCT04525300
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities
ObesityPhase 3unknown2020-05 → 2022-06300unknownNCT04525300
STEP 8
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
ObesityPhase 3completed2019-09 → 2021-03338Completed; results not in the atlas yetNCT04074161
NCT03421119
Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
T2DPhase 3unknown2019-06 → 2019-12300unknownNCT03421119
REMITiDegLira
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
T2DPhase 3completed2019-04 → 2022-06159Completed; results not in the atlas yetNCT03862716
NATRIURETIC
Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
HFpEFPhase 2completed2019-03 → 2021-036Completed; results not in the atlas yetNCT04535960
NCT03737240
IDegLira HIGH Trial
T2DPhase 3completed2019-01 → 2022-07145Completed; results not in the atlas yetNCT03737240
DAL
Daily Liraglutide for Nicotine Dependence
AddictionPhase 2completed2018-11 → 2022-0540Completed; results not in the atlas yetNCT03712098
NCT03707171
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
Alzheimer'sPhase 3completed2018-10 → 2019-0230Completed; results not in the atlas yetNCT03707171
SAXAPCOS
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
ObesityPhase 3completed2018-09 → 2021-0288Completed; results not in the atlas yetNCT03480022
NCT03671733
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
ObesityPhase 3unknown2018-09 → 2022-09150unknownNCT03671733
NCT03672812
The Use of Liraglutide in Brain Death
OtherPhase 3completed2018-09 → 2019-1250Completed; results not in the atlas yetNCT03672812
NCT03374956
Individualized Obesity Pharmacotherapy
ObesityPhase 3completed2017-12 → 2022-05193Completed; results not in the atlas yetNCT03374956
BELIEVE
Binge Eating Liraglutide Intervention
AddictionPhase 3terminated2017-09 → 2019-0936TerminatedNCT03279731
NCT03115424
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
ObesityPhase 3completed2017-06 → 2023-1046Completed; results not in the atlas yetNCT03115424
SUSTAIN 10
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
T2DPhase 3completed2017-06 → 2018-07577Completed; results not in the atlas yetNCT03191396
DUAL I China
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
T2DPhase 3completed2017-05 → 2019-06720Completed; results not in the atlas yetNCT03172494
DUAL II China
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
T2DPhase 3completed2017-05 → 2019-03453Completed; results not in the atlas yetNCT03175120
NCT02953665
Safety and Efficacy of Liraglutide in Parkinson's Disease
NeurologyPhase 2completed2017-04 → 2022-0863Completed; results not in the atlas yetNCT02953665
LIRA-ADD2SGLT2i
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
T2DPhase 3completed2017-03 → 2018-05303Completed; results not in the atlas yetNCT02964247
SCALE Insulin
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
ObesityPhase 3completed2017-02 → 2018-09396Completed; results not in the atlas yetNCT02963922
SCALE IBT
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
ObesityPhase 3completed2017-02 → 2018-05282Completed; results not in the atlas yetNCT02963935
PIONEER 9
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
T2DPhase 3completed2017-01 → 2018-01243Completed; results not in the atlas yetNCT03018028
LIRALUNG Study
Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
T2DPhase 3completed2016-10 → 2019-1176Completed; results not in the atlas yetNCT02889510
DUAL II Japan
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
T2DPhase 3completed2016-09 → 2017-11210Completed; results not in the atlas yetNCT02911948
NCT02918279
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
ObesityPhase 3completed2016-09 → 2019-02251Completed; results not in the atlas yetNCT02918279
PIONEER 4
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
T2DPhase 3completed2016-08 → 2017-08711Completed; results not in the atlas yetNCT02863419
NCT04325581
Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients
ObesityPhase 3completed2016-08 → 2018-1216Completed; results not in the atlas yetNCT04325581
LixiLan-G
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
T2DPhase 3completed2016-07 → 2018-05514Completed; results not in the atlas yetNCT02787551
i-LAB
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
T2DPhase 3unknown2016-06 → 2017-0320unknownNCT02718950
DUAL IX
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
T2DPhase 3completed2016-05 → 2017-09420Completed; results not in the atlas yetNCT02773368
NCT03426085
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
NeurologyPhase 2unknown2016-05 → 2020-0444unknownNCT03426085
DUAL VIII
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
T2DPhase 3completed2016-01 → 2018-101012Completed; results not in the atlas yetNCT02501161
NCT02638805
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
T2DPhase 3completed2015-12 → 2017-10136Completed; results not in the atlas yetNCT02638805
NCT02527200
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
ObesityPhase 3completed2015-11 → 2020-1156Completed; results not in the atlas yetNCT02527200
DUAL I Japan
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
T2DPhase 3completed2015-11 → 2017-12819Completed; results not in the atlas yetNCT02607306
NCT02420262
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
T2DPhase 3completed2015-07 → 2016-10506Completed; results not in the atlas yetNCT02420262
NCT02505334 · Japan
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
T2DPhase 3completed2015-07 → 2017-05635Completed; results not in the atlas yetNCT02505334
COGDYS-GLP1
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
Alzheimer'sPhase 3completed2015-05 → 2016-0421Completed; results not in the atlas yetNCT02423824
LEADER
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
CV outcomesPhase 3completed2010-08 → 2015-129341MACE HR 0.87 (0.78–0.97)NCT01179048

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Liraglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/liraglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.